35 results
6-K
EX-99
RLFTF
Relief Therapeutics Holding AG
28 Oct 24
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
4:57pm
and commercial goals, and other factors which could cause the actual results, financial condition, performance or achievements of Relief to be materially
6-K
EX-99
RLFTF
Relief Therapeutics Holding AG
22 Oct 24
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
5:30pm
ability to achieve its corporate, development and commercial goals, and other factors which could cause the actual results, financial condition
6-K
EX-99
RLFTF
Relief Therapeutics Holding AG
9 Oct 24
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
4:30pm
risks, uncertainties, including its ability to achieve its corporate, development and commercial goals, and other factors which could cause the actual
6-K
EX-99
RLFTF
Relief Therapeutics Holding AG
7 Oct 24
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
4:35pm
goals, and other factors which could cause the actual results, financial condition, performance or achievements of Relief to be materially different from
6-K
EX-99
RLFTF
Relief Therapeutics Holding AG
23 Sep 24
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
4:30pm
involve known and unknown risks, uncertainties, including its ability to achieve its corporate, development and commercial goals, and other factors
6-K
EX-99
9xwzbg54
19 Sep 24
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024
4:47pm
6-K
EX-99
xe2xb
4 Sep 24
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
5:11pm
6-K
EX-99.3
xvp c3pc426s
30 Aug 24
Current report (foreign)
4:32pm
6-K
EX-99
ec976
6 Aug 24
Form 6-K Report of Foreign Private Issuer for August, 2024
5:01pm
6-K
EX-99
9q9uog0g ef5f7qha1yg
28 Jun 24
RELIEF THERAPEUTICS Holding SA Announces Results of
4:30pm
6-K
EX-99
59nhlytdsfmdslkxs24y
3 Jun 24
Invitation to the Annual Shareholders' Meeting of RELIEF THERAPEUTICS Holding SA
5:06pm
6-K
EX-99
kn69fx 58bmc
3 Jun 24
Invitation to the Annual Shareholders' Meeting of RELIEF THERAPEUTICS Holding SA
5:06pm
6-K
EX-99
9ww0 9ny8rm
10 May 24
Relief Therapeutics Announces New Executive Leadership Team strengthening capabilities to guide the Company through pipeline development initiatives
4:30pm
6-K
EX-99
1jnrhnff65gj2gfzkmb
3 Apr 24
Invitation to the Extraordinary Shareholders' Meeting of RELIEF THERAPEUTICS Holding SA
4:31pm
6-K
EX-99
q0ccgqzgj5p2b6y
27 Mar 24
Form 6-K Report of Foreign Private Issuer for March, 2024
4:15pm
6-K
EX-99
80j94b6 2g
28 Feb 24
Form 6-K Report of Foreign Private Issuer for February, 2024
5:00pm
6-K
EX-99
gey7detba 4eo
5 Dec 23
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
4:30pm